Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has U.S. offices in Palo Alto, CA and Philadelphia, PA, and has offices in various other locations in Europe. The company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. We plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our unique commercial expertise. As we evaluate additional acquisition and in-licensing opportunities, we work closely with healthcare professionals and patient advocates to identify significant treatment gaps where Jazz Pharmaceuticals’ unique approach to patient care and patient-focused products may be able to bring a new therapeutic option to the market where none existed previously.
Type
Public
HQ
Ballsbridge, IE
Founded
2003
Size (employees)
857 (est)+23%
Jazz Pharmaceuticals was founded in 2003 and is headquartered in Ballsbridge, IE

Key People at Jazz Pharmaceuticals

Bruce C. Cozadd

Bruce C. Cozadd

Chairman and Chief Executive Officer
Heather McGaughey

Heather McGaughey

Senior Vice President, Human Resources
Fintan Keegan

Fintan Keegan

Executive Vice President, Technical Operations
Russell J. Cox

Russell J. Cox

Executive Vice President and Chief Commercial Officer
Iain McGill

Iain McGill

Head of EUSA International and SVP, Jazz Pharmaceuticals

Jazz Pharmaceuticals Office Locations

Jazz Pharmaceuticals has offices in Ballsbridge, Palo Alto, Philadelphia and Oxford
Ballsbridge, IE (HQ)
Connaught House Burlington Rd
Oxford, GB
Oxford Business Park
Philadelphia, US
2350 1818 Market St
Palo Alto, US
3180 Porter Drive

Jazz Pharmaceuticals Data and Metrics

Jazz Pharmaceuticals Financial Metrics

Jazz Pharmaceuticals's revenue was reported to be $1.5 b in FY, 2016
USD

Revenue (FY, 2016)

1.5 b

Gross profit (FY, 2016)

1.4 b

Gross profit margin (FY, 2016), %

93%

Net income (FY, 2016)

396.8 m

EBIT (FY, 2016)

591.7 m

Market capitalization (21-Jul-2017)

9.7 b

Closing share price (21-Jul-2017)

159.9

Cash (31-Dec-2016)

366 m

EV

9.3 b
Jazz Pharmaceuticals's current market capitalization is $9.7 b.
USDFY, 2016

Revenue

1.5 b

Cost of goods sold

105.4 m

Gross profit

1.4 b

Gross profit Margin, %

93%

R&D expense

162.3 m

General and administrative expense

502.9 m

Operating expense total

896.3 m

EBIT

591.7 m

EBIT margin, %

40%

Interest expense

(61.9 m)

Income tax expense

135.2 m

Net Income

396.8 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

636.5 m684 m988.8 m366 m

Inventories

28.7 m30 m19.5 m34.1 m

Current Assets

864.6 m1 b1.3 b748.1 m

PP&E

14.2 m58.4 m85.6 m107.5 m

Goodwill

450.5 m702.7 m657.1 m893.8 m

Total Assets

2.2 b3.3 b3.4 b4.8 b

Accounts Payable

21 m25.1 m21.8 m22.4 m

Total Debt

36.1 m

Current Liabilities

204 m216.8 m226.6 m257.4 m

Additional Paid-in Capital

1.2 b1.5 b1.6 b1.7 b

Retained Earnings

18.5 m34.7 m302.7 m528.9 m

Total Equity

1.6 b1.9 b

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

2.1 x2.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

216.3 m57.3 m329.5 m396.8 m

Depreciation and Amortization

82.1 m133.7 m9.9 m11.8 m

Accounts Receivable

(49 m)(55 m)(25 m)(25.6 m)

Inventories

(8.5 m)(7.6 m)6.3 m(17 m)

Accounts Payable

5.1 m(38 m)(2.3 m)361 k

Cash From Operating Activities

283.6 m405.8 m531.9 m590.5 m

Purchases of PP&E

(10 m)(36.3 m)(36 m)(7.8 m)

Cash From Investing Activities

(11.3 m)(1.1 b)(2.3 m)(1.7 b)

Long-term Borrowings

(465.9 m)(9.5 m)(905.8 m)(28.3 m)

Cash From Financing Activities

(24 m)712.9 m(214.3 m)541 m

Interest Paid

18.3 m32 m40.1 m39.9 m

Income Taxes Paid

137.6 m108.2 m145.6 m160.3 m
USDY, 2016

EV/EBIT

15.8 x

EV/CFO

15.8 x

Revenue/Employee

1.7 m

Financial Leverage

2.6 x

Jazz Pharmaceuticals Market Value History

Jazz Pharmaceuticals Median Salaries

Source: 18 public H-1B filings from Jazz Pharmaceuticals

Jazz Pharmaceuticals Online and Social Media Presence

Jazz Pharmaceuticals News and Updates

Jazz Pharmaceuticals Company Life and Culture

You may also be interested in